S2212 SCARLET

Breast Cancer

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

Key Team Members

Principal Investigator

Steven A. Madden, MD

Research Coordinator

Katharine "Kate" Madden

Accepting Patients

Enrollment Started: August 25, 2023

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The S2212 SCARLET trial is a Phase III clinical trial testing whether a shorter, "anthracycline-free" treatment plan works as well as the standard treatment for early-stage triple-negative breast cancer (TNBC). The goal is to reduce side effects by using fewer chemotherapy drugs without compromising the effectiveness of the treatment.